DURECT Corp (DRRX) Says FDA Committee Review Date for REMOXY NDA Set for Aug. 5th
Tweet Send to a Friend
DURECT Corporation (Nasdaq: DRRX) announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE